1. Home
  2. KELYA vs AVTX Comparison

KELYA vs AVTX Comparison

Compare KELYA & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kelly Services Inc.

KELYA

Kelly Services Inc.

HOLD

Current Price

$11.94

Market Cap

340.1M

ML Signal

HOLD

Logo Avalo Therapeutics Inc.

AVTX

Avalo Therapeutics Inc.

HOLD

Current Price

$14.65

Market Cap

328.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KELYA
AVTX
Founded
1946
2011
Country
United States
United States
Employees
4900
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
340.1M
328.4M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
KELYA
AVTX
Price
$11.94
$14.65
Analyst Decision
Buy
Strong Buy
Analyst Count
1
8
Target Price
$15.00
$40.57
AVG Volume (30 Days)
475.6K
1.4M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
3.07%
N/A
EPS Growth
N/A
72.07
EPS
N/A
N/A
Revenue
N/A
$27,813,137.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2312.27
52 Week Low
$7.98
$4.46
52 Week High
$14.94
$24.27

Technical Indicators

Market Signals
Indicator
KELYA
AVTX
Relative Strength Index (RSI) 68.86 47.23
Support Level $8.30 $13.22
Resistance Level $12.01 $15.63
Average True Range (ATR) 0.44 0.93
MACD 0.01 -0.16
Stochastic Oscillator 84.21 53.09

Price Performance

Historical Comparison
KELYA
AVTX

About KELYA Kelly Services Inc.

Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Share on Social Networks: